Patrick H. Higgins


  • Wednesday, December 1, 2004
    We are at a similar crossroads today with respect to generic biopharmaceuticals as we were in 1984 with respect to traditional pharmaceuticals. This article briefly reviews the fundamentals of market exclusivity in the drug-discovery industry and a series of rapidly evolving issues related to prospects for a streamlined regulatory approval process for "...